Effects of entecavir and telbivudine on renal function in patients with compensatory hepatitis B cirrhosis

Objective To investigate the effects of entecavir and telbivudine on renal function in patients with compensatory hepatitis B cirrhosis. Methods 150 patients with compensatory hepatitis B cirrhosis admitted to our hospital from March, 2015 to September, 2016 were selected for study, and were randomly divided into an observation group and a control group, 75 cases for each group. The observation group was treated with telbivudine, and the control group with entecavir. After 96 weeks’ treatment, the normalization rate of alanine aminotransferase (ALT), HBeAg conversion rate, negative rate of HBV DNA, serum creatinine (Cr), estimated glomerular filtration rate (eGFR), and adverse reactions were compared between the two group. Results One patient (1.33%) in the observation group and four (5.33%) in the control group did not complete the study. The ALT normalization rate and HBeAg conversion rate were higher and the HBV DNA negative conversion rate was lower in the observation group than in the control group, but with no statistical differences (all P>0.05). There were no statistical differences in Cr and eGFR between the two groups before the treatment (both P>0.05). After the treatment, the Cr was lower and the eGFR was higher after than before the treatment in the observation group, and were better in the observation group than in the control group after 48 and 96 weeks’ treatment, with statistical differences (P 0.05). Conclusion Telbivudine and entecavir for patients with compensatory hepatitis B cirrhosis both are antivirally effective, but telbivudine improves the renal function more obviously. Key words: Hepatitis B; Compensation period; Telbivudine; Entecavir; Renal function